PMC:7195088 / 1553-2199 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"21","span":{"begin":247,"end":255},"obj":"Species"},{"id":"23","span":{"begin":238,"end":246},"obj":"Disease"},{"id":"30","span":{"begin":271,"end":318},"obj":"Species"},{"id":"31","span":{"begin":320,"end":330},"obj":"Species"},{"id":"33","span":{"begin":358,"end":382},"obj":"Disease"},{"id":"34","span":{"begin":384,"end":392},"obj":"Disease"},{"id":"35","span":{"begin":572,"end":591},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Tax:9606"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"MESH:C000657245"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Tax:2697049"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"Tax:2697049"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:C000657245"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:C000657245"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:D012131"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"tive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients.\n\nIntroduction\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which has rapidly become epidemic in Italy and other European countries [[1], [2], [3]]. The disease spectrum ranges from asymptomatic/mildly symptomatic presentations to acute respiratory failure, with the true proportion of severe cases still remain"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T2","span":{"begin":572,"end":591},"obj":"Phenotype"}],"attributes":[{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002878"}],"text":"tive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients.\n\nIntroduction\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which has rapidly become epidemic in Italy and other European countries [[1], [2], [3]]. The disease spectrum ranges from asymptomatic/mildly symptomatic presentations to acute respiratory failure, with the true proportion of severe cases still remain"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T10","span":{"begin":238,"end":246},"obj":"Disease"},{"id":"T11","span":{"begin":271,"end":318},"obj":"Disease"},{"id":"T12","span":{"begin":320,"end":328},"obj":"Disease"},{"id":"T13","span":{"begin":358,"end":382},"obj":"Disease"},{"id":"T14","span":{"begin":384,"end":392},"obj":"Disease"},{"id":"T15","span":{"begin":566,"end":591},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0001208"},{"id":"A16","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"}],"text":"tive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients.\n\nIntroduction\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which has rapidly become epidemic in Italy and other European countries [[1], [2], [3]]. The disease spectrum ranges from asymptomatic/mildly symptomatic presentations to acute respiratory failure, with the true proportion of severe cases still remain"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T5","span":{"begin":401,"end":404},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"tive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients.\n\nIntroduction\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which has rapidly become epidemic in Italy and other European countries [[1], [2], [3]]. The disease spectrum ranges from asymptomatic/mildly symptomatic presentations to acute respiratory failure, with the true proportion of severe cases still remain"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":71,"end":77},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_34922"}],"text":"tive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients.\n\nIntroduction\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which has rapidly become epidemic in Italy and other European countries [[1], [2], [3]]. The disease spectrum ranges from asymptomatic/mildly symptomatic presentations to acute respiratory failure, with the true proportion of severe cases still remain"}

{"project":"LitCovid-sentences","denotations":[{"id":"T16","span":{"begin":71,"end":256},"obj":"Sentence"},{"id":"T17","span":{"begin":258,"end":270},"obj":"Sentence"},{"id":"T18","span":{"begin":271,"end":483},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"tive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients.\n\nIntroduction\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which has rapidly become epidemic in Italy and other European countries [[1], [2], [3]]. The disease spectrum ranges from asymptomatic/mildly symptomatic presentations to acute respiratory failure, with the true proportion of severe cases still remain"}